On May 28, 9:36=A0am, ironjustice <teamtan...@[EMAIL PROTECTED]
> wrote:confirm
vigorously that unsaturated phosphatidylcholine (USPC) is the
endogenous species inside the joint <<
"Unsaturated phosphatidylcholine in the treatment and/or prophylaxis
of particular medical conditions such as osteoarthritis and for
lubricating interactive surfaces in artificial joints."
(WO/2005/027933) UNSATURATED PHOSPHATIDYLCHOLINES AND USES THEREOF
Biblio. Data Description Claims National PhaseNoticesDo***ents Latest
bibliographic data on file with the International Bureau
----------------------------------------------------------------------------=
----
Pub. No.: WO/2005/027933 International Application No.: PCT/
AU2004/001290
Publication Date: 31.03.2005 International Filing Date: 21.09.2004
Chapter 2 Demand Filed: 22.07.2005
IPC: A61K 31/6615 (2006.01), A61K 31/685 (2006.01)
Applicants: THE COR****ATION OF THE TRUSTEES OF THE ORDER OF THE
SISTERS OF MERCY IN QUEENSLAND [AU/AU]; Raymond Terrace, South
Brisbane, Queensland 4101 (AU) (All Except US).
CHEN, Yi [AU/AU]; 15 Love Street, Fairfield, Queensland 4103 (AU) (US
Only).
HILLS, Brian, Andrew [AU/AU]; 29 Peach Treet Close, Alexandra Hills,
Queensland 4161 (AU) (US Only).
Inventors: CHEN, Yi [AU/AU]; 15 Love Street, Fairfield, Queensland
4103 (AU).
HILLS, Brian, Andrew [AU/AU]; 29 Peach Treet Close, Alexandra Hills,
Queensland 4161 (AU).
Agent: HUGHES, E, John, L; Davies Collison Cave, 1 Nicholson Street,
Melbourne, Victoria 3000 (AU).
Priority Data: 2003905186 23.09.2003 AU
2004901087 02.03.2004 AU
Title: UNSATURATED PHOSPHATIDYLCHOLINES AND USES THEREOF
Abstract: The present invention relates generally to a method for
providing formation, ultrafiltration and/or lubrication between two or
more opposing or in contact surfaces. More particularly, the present
invention effects one or more of surface tension reduction anti-stick,
barrier formation, ultrafiltration, lubrication and/or effector of
cellular therapeutic, and regeneration between two or more surfaces by
the application or absorption of an unsaturated phosphatidylcholine
alone or in combination with a saturated phosphatidylcholine. The
present invention further provides compositions comprising unsaturated
phosphatidylcholine species alone or in combination with a saturated
phosphatidylcholine and their use in the treatment and/or prophylaxis
of particular medical conditions such as osteoarthritis, surgical
adhesion, burns injuries, ocular disorders, ultra-filtration failure
in peritoneal dialysis, barrier disorders of the skin and mucosa,
middle ear disorders, as a facilitation of cellular therapeutics and
regenerative medicine and for lubricating interactive surfaces in
artificial joints.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY,
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE,
LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
> On May 26, 10:37=A0am, tony sayer <t...@[EMAIL PROTECTED]
> wrote:Well there
> we have it!, we're all in need of some Castrol as we're all going
> rusty;!..... <<
>
> It IS just as simple as that .. but spelled different ..
>
> Castor .. oil ..
>
> The iron **selectively** destroys the 'lubricant' around the joints
> and =A0castor oil is one of many plant oils which contain this lubricant
> and soooo eating it seems to be the way one might replace it.
>
> Lack Of Critical Lubricant Causes Wear In Joints, First-Ever Study
> Finds
> Main Category: Arthritis News
> Article Date: 07 Nov 2007 - 1:00 PST
>
> Mice that don't produce lubricin, a thin film of protein found in the
> cartilage of joints, showed early wear and higher friction in their
> joints, a new study led by Brown University researchers shows.
>
> This link between increased friction and early wear in joints is a
> first; no other team of scientists has proven this association
> before.
> The finding, published in Arthritis & Rheumatism, sheds im****tant
> light on how joints work. The discovery also suggests that lubricin,
> or a close cousin, could be injected directly into hips, knees or
> other joints inflamed from arthritis or injury -- a preventive
> treatment that could reduce the need for painful and costly joint
> replacement surgery.
>
> In an editorial that accompanies the journal article, orthopedics
> researchers from Rush University Medical Center in Chicago call the
> research an "im****tant contribution to the field" and note that the
> use of biomolecules like lubricin to prevent joint wear "could have a
> substantial clinical impact, if successful."
>
> Gregory Jay, M.D, a Rhode Island Hospital emergency physician and an
> associate professor of emergency medicine and engineering at Brown,
> led the research. For 20 years, Jay has studied lubricin's role as a
> "boundary lubricant" by reducing friction between opposing layers of
> cartilage inside joints. In this new work, Jay and his colleagues set
> out to answer the next question: Does reducing friction actually
> prevent wear, or surface damage, in joints?
>
> To find out, Jay and his team studied cartilage from the knees of
> mice
> that don't produce lubricin. Directly after birth, the cartilage was
> smooth. But in as little as two weeks, researchers found, the
> cartilage began to show signs of wear. Under an electron microscope,
> scientists could see that the collagen fibers that cartilage is
> composed of were breaking up, giving the surface a rough, frayed
> appearance. This damage is called wear, an early sign of joint
> disease
> or injury.
>
> Jay and his team then took the work a step further. To better
> understand how lubricin works, they tried to see the structure of the
> film. So they put a tiny bit of the protein under an atomic force
> microscope. At the nanoscale, the molecule appeared as a mesh -- row
> upon row of interlocking fibers -- that could repel a microscope
> probe. This repulsion, created with water and electrical charges,
> shows how lubricin acts as a buffer, keeping opposing layers of
> cartilage apart.
>
> "We demonstrated that lubricin reduces both friction and wear and
> also
> showed how, on a molecular level, it does this work in the body," Jay
> said. "What's exciting are the clinical implications. Arthritis and
> s****ts injuries damage the joints of thousands of people in the
> United
> States and millions of people worldwide each year. Our aim is to make
> a treatment that can actually prevent wear in the joints."
>
> Through Rhode Island Hospital, Jay has filed two patents on the
> protein and its sequences and, in 2004, helped form Tribologics, a
> biotech company formed out of Rhode Island Hospital. The
> Massaschusetts-based business is developing an injection treatment
> for
> inflamed joints that contains lubricin.
>
> Members of the research team included Jahn Torres, a former Brown
> graduate student in engineering; David Rhee, a former graduate
> student
> at Case Western Reserve University; Heikki Helminen, M.D., and Mika
> Hytinnen, M.D., from the University of Kuopio in Finland; Chung-Ja
> Cha, a research assistant at Rhode Island Hospital; Khaled Elsaid, a
> postdoctoral research fellow at Rhode Island Hospital; Kyung-Suk Kim,
> a professor of engineering at Brown; and Yajun Cui, M.D., and Matthew
> Warman, M.D., of Boston Children's Hospital and Harvard Medical
> School.
>
> The National Institute of Arthritis and Musculoskelatal and Skin
> Diseases funded the work, along with the Academy of Finland, the
> McCutchen Foundation, the Howard Hughes Medical Institute and the
> Burroughs Wellcome Fund.
>
> Source: Wendy Lawton
> Brown University
>
> --------------------------------------------------
>
> J Orthop Surg. 2007 Aug 23;2(1):14 [Epub ahead of print] Links
> Unsaturated phosphatidylcholines lining on the surface of cartilage
> and its possible physiological roles.
> Chen Y, Crawford RW, Oloyede A.
> ABSTRACT:
> BACKGROUND:
> Evidence has strongly indicated that surface-active phospholipid
> (SAPL), or surfactant, lines the surface of cartilage and serves as a
> lubricating agent. Previous clinical study showed that a saturated
> phosphatidylcholine (SPC), dipalmitoyl-phosphatidylcholine (DPPC),
> was
> effective in the treatment of osteoarthritis, however recent studies
> suggested that the dominant SAPL species at some sites outside the
> lung are not SPC, rather, are unsaturated phosphatidylcholine (USPC).
> Some of these USPC have been proven to be good boundary lubricants by
> our previous study, implicating their possible im****tant
> physiological
> roles in joint if their existence can be confirmed. So far, no study
> has been conducted to identify the whole molecule species of
> different
> phosphatidylcholine (PC) cl***** on the surface of cartilage. In this
> study we identified the dominant PC molecule species on the surface
> of
> cartilage. We also confirmed that some of these PC species possess a
> property of semipermeability.
> METHODS:
> HPLC was used to analyse the PC profile of bovine cartilage samples
> and comparisons of DPPC and USPC were carried out through
> semipermeability tests.
> RESULTS:
> It was confirmed that USPC are the dominant SAPL species on the
> surface of cartilage. In particular, they are Dilinoleoyl-
> phosphatidylcholine (DLPC), Palmitoyl-linoleoyl-phosphatidylcholine,
> (PLPC), Palmitoyl-oleoyl-phosphatidylcholine (POPC) and Stearoyl-
> linoleoyl-phosphatidylcholine (SLPC). The relative content of DPPC (a
> SPC) was only 8%. Two USPC, PLPC and POPC, were capable of generating
> osmotic pressure that is equivalent to that by DPPC.
> CONCLUSIONS:
> The results from the current study confirm vigorously that USPC is
> the
> endogenous species inside the joint as against DPPC thereby
> confirming
> once again that USPC, and not SPC, characterizes the PC species
> distribution at non-lung sites of the body. USPC not only has better
> anti-friction and lubrication properties than DPPC, they also possess
> a level of semipermeability that is equivalent to DPPC. We therefore
> hypothesize that USPC can constitute a possible addition or
> alternative to the current commercially available
> viscosupplementation
> products for the prevention and treatment of osteoarthritis in the
> future.
>
> PMID: 17718898 [PubMed - as supplied by publisher]
>
>
--------------------------------------------------------------------------=
-=AD=AD=AD=AD-----
>
> Who loves ya.
> Tom
>
> Jesus Was A Vegetarian!http://tinyurl.com/2r2nkh
>
> Man Is A Herbivore!http://tinyurl.com/a3cc3
>
> DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk
>
>
>
> > >2] Drugs used to treat arthritis commonly are iron binding / iron
> > >targeting .. drugs ..
>
> > >IE: aspirin,indomethacin,sulfasalazine,
>
> > >3] Reduction of iron is recommended in the treatment of gout ..
>
> > >4] Oxidative stress has been shown to be elevated in those with
> > >arthritis and iron reduction is shown to alleviate oxidative stress.
>
> > >5] Iron restricted diet has been shown to alleviate symptoms of
> > >arthritis.
>
> > >6] Introduction of iron rich blood into the joint induces / causes
> > >arthritis
>
> > >7] Introduction of iron into the joint induces / causes arthritis
>
> > >8] Those with diagnosed iron overload have a very high incidence of
> > >arthritis
>
> > >9] Iron levels have recently been recommended to be tested in ALL
> > >those
> > >who manifest unexplained joint pain ..
>
> > >10] The fact they have admitted to inadvertently **killing** millions
> > >of people by not being **able** to diagnose iron levels in the body.
>
> > >IE: malaria patients treated with iron and folic acid
>
> > >11] The fact they have admitted to inadvertently killing Aids
> > >patients
> > >by giving them iron.
>
> > >12] The fact they have only recently found all diabetics to have free
> > >floating unbound iron in their bodies when they had argued there was
> > >no
> > >iron at all.
>
> > >13} Iron ac***ulates excessively in joints in those with arthritis.
> > >Tom
>
> > Well there we have it!, we're all in need of some Castrol as we're all
> > going rusty;!.....
>
> > --
> > Tony Sayer- Hide quoted text -
>
> > - Show quoted text -- Hide quoted text -
>
> - Show quoted text -
|
